URETHANE THERAPY IN LEUKEMIA

Urethane therapy in leukemia.

T HE purpose of this paper is to report the results of urethane therapy of the leukemias, based on a study of 2.4 patients. In April, 1946, Haddow and Sexton’ described the influence of various carbamic esters on experimental rat cancers. Ethyl carbamate (urethane) yielded the best results. It alone produced inhibition of tumor growth and fibrous replacement of the cancerous rat tissue. For thi...

The Use of Urethane (ethyl Carbamate) in the Treatment of Leukemia

H ADDOW and Sexton’ noted a coincidental depression of the leukocyte count during the course of observations on the effect of various forms of urethane On the growth of experimentally produced tumors in the rat. As a result, the various forms of urethane, principally ethyl carbamate, were subsequently utilized in the treatment of leukemias and other types of malignant disease by Paterson, Thoma...

Therapy-related myeloid leukemia.

One of the most serious possible consequences of cancer therapy is the development of a second cancer, especially leukemia. Several distinct subsets of therapy-related leukemia can be distinguished currently. These include classic therapy-related myeloid leukemia, leukemia that follows treatment with agents that inhibit topoisomerase II, acute lymphoblastic leukemia, and leukemias with 21q22 re...

Therapy-related myeloid leukemia following Pleuropulmonary blastoma: A case report

The development of secondary malignancy (SM) is the most worrisome long-term complication of childhood cancer. Acute myeloid leukemia is the most prevalent neoplasm that occurs after treatment with alkylating agents and topoisomerase II inhibitors. Pleuropulmonary blastoma (PPB) is a rare lung neoplasm in children. Type II and type III of this cancer are markedly aggressive and have a recurrent...

Drug Switching, a Creative Approach to Leukemia Therapy